Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brilinta Tablets 60mg/90mg Clinical Experience Investigation

Trial Profile

Brilinta Tablets 60mg/90mg Clinical Experience Investigation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2018

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BRLCEIACS/OMI
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Sep 2018 Planned End Date changed from 21 Aug 2024 to 28 Jun 2024.
    • 03 Sep 2018 Planned primary completion date changed from 21 Aug 2024 to 28 Jun 2024.
    • 27 Dec 2017 Planned End Date changed from 28 Aug 2024 to 21 Aug 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top